Abcuro Stock

abcuro.comHealthcare / BioTech & PharmaFounded: 2015Funding to Date: $207.25MM

Abcuro is an immuno-therapeutic company aiming to help treat cancer and autoimmune diseases. Using pre-clinical antibody development, Abcuro develops clinical treatments that target lektin receptors on cytotoxic T cells. Other advancements being made in the company include the ABC015 anti-KLRG1 blocking antibody. Abcuro was founded by Stefano Gullà in 2015 and is headquartered in Boston, MA.

Register To Buy and Sell Shares

For more details on financing and valuation for Abcuro, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in


Enterprise Value

Powered by Forge Data

Access Abcuro’s valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Abcuro.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.


Animation displayed is not current and securities are shown for illustrative purposes only.

Abcuro’s stock FAQs


Can you buy Abcuro’s stock?

Abcuro is not publicly traded on NYSE or NASDAQ in the U.S. To buy Abcuro’s stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.

Can you sell Abcuro’s stock?

Yes, you can sell stock of a private company like Abcuro. Forge can help you sell your Abcuro stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.

What is Abcuro’s stock price?

Abcuro is a privately held company and therefore does not have a public stock price. However, you may access Abcuro’s private market stock price with Forge Data.

What is Abcuro’s stock ticker symbol?

Abcuro does not have an official ticker symbol because this company is not currently publicly traded.

Can institutional investors buy and sell private market stocks?

Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

News Highlights

Abcuro raises $155m for KLRG1 drug trial

Abcuro raised new funding to further develop autoimmune therapy drugs.
Updated on: Jun 18, 2024


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.